Myocardial Infarction News and Research

RSS

Lessons learned from transfusion refusal

Jehovah’s Witness patients who refuse blood transfusions during cardiac surgery are not at risk for surgical complications or long-term mortality compared with non-Witnesses who receive transfusions, report US researchers.

10 Jul 2012

BP variability link to stroke risk reinforced

Analysis of data from the Women’s Health Initiative supports the contention that variability in a person’s blood pressure affects their risk for stroke.

10 Jul 2012

Peripheral arterial disease predicts mortality in TAVI patients

Patients with severe aortic stenosis who undergo transcatheter aortic valve implantation are at particularly high risk for complications and death if they also have concomitant peripheral arterial disease, study results show.

10 Jul 2012

COPD still affects treatment received after heart attack

Patients with chronic obstructive pulmonary disease receive less aggressive treatment after hospitalization for acute myocardial infarction than those without the lung condition, US study results show.

10 Jul 2012

Jehovah’s Witnesses’ beliefs do not necessarily put them at risk

Jehovah’s Witnesses do not have a significantly increased risk for complications or long-term mortality after cardiac surgery, researchers say.

10 Jul 2012

Treatment of Schizophrenia receives notice of intention to grant a European patent

BioLineRx (NASDAQ:BLRX)(TASE:BLRX), a biopharmaceutical development company, announced today that it has received from the European Patent Office a notice of intention to grant a European patent claiming the salt of BL-1020, a first-in-class orally available treatment for schizophrenia.

9 Jul 2012

FDA approves Capricor’s IND application for myocardial infarction study

Capricor, Inc., a privately held biotechnology company focused on regenerative medicine, today announced that the U.S. Food and Drug Administration has approved initiation of its Investigational New Drug (IND) application for the ALLSTAR study, which will use allogeneic cardiac-derived stem cells (CDCs) to treat patients following large myocardial infarctions (MI).

9 Jul 2012

Two coffees a day keep heart failure risk at bay

Drinking two cups of coffee a day may significantly reduce risk for heart failure, while anymore than that could significantly increase the risk, researchers say.

27 Jun 2012

Magnet guides iron-loaded cells to specific damaged sites in the heart

Optimal stem cell therapy delivery to damaged areas of the heart after myocardial infarction has been hampered by inefficient homing of cells to the damaged site. However, using rat models, researchers in France have used a magnet to guide cells loaded with iron oxide nanoparticles to key sites, enhancing the myocardial retention of intravascularly delivered endothelial progenitor cells.

27 Jun 2012

Poor prognosis for heart transplant patients with restenosis

Orthotopic heart transplant patients who develop in-stent restenosis after percutaneous coronary intervention have a poor long-term prognosis, research suggests.

26 Jun 2012

Experts validate promising alternative to Framingham risk score for UK

Researchers have validated an alternative model to the Framingham risk equation for the prediction of 10-year cardiovascular disease risk in the UK, they report in the BMJ.

26 Jun 2012

Chronic kidney disease is major risk factor for future coronary events

People with chronic kidney disease have a 10-year risk for myocardial infarction of around 12%, report researchers who found that this was higher than that for people with diabetes.

26 Jun 2012

Researchers develop inexpensive system that offers benefits of cardiac rehabilitation programmes

Researchers at the Universidad Poltécnica de Madrid (UPM) have developed an inexpensive system that offers the benefits of cardiac rehabilitation programmes for patients who currently cannot access them.

26 Jun 2012

Turn down the volume to improve heart health

Individuals who live in an area that is exposed to high road traffic noise have a significantly increased risk for myocardial infarction (MI), researchers suggest.

25 Jun 2012

Enrollment commences in Stealth Peptides' Bendavia Phase II clinical study for acute STEMI

Stealth Peptides Incorporated, a privately held biopharmaceutical company developing innovative therapies for cardiovascular disease and its complications, announced today that the first patient was enrolled in its multinational Phase II clinical study with Bendavia focused on ischemia reperfusion and microvascular injuries for patients experiencing acute ST-segment elevation myocardial infarction.

25 Jun 2012

Skin disease shares common inflammatory pathway with metabolic disorder

Psoriasis is an independent risk for Type 2 Diabetes, according to a new study by researchers with the Perelman School of Medicine at the University of Pennsylvania, with the greatest risk seen in patients with severe psoriasis.

19 Jun 2012

Sanofi’s insulin glargine delays progression from pre-diabetes to T2DM

Sanofi presented results from the landmark ORIGIN trial (Outcome Reduction with Initial Glargine Intervention) at the American Diabetes Association 72nd Scientific sessions. The key findings showed that, compared to standard care, Lantus(insulin glargine [rDNA] injection) had no statistically significant positive or negative impact on cardiovascular (CV) outcomes versus standard care during the study period and that there was no association between insulin glargine use and increased risk of any cancer.

15 Jun 2012

STENTYS initiates enrollment in Self-Apposing Sirolimus-eluting stent trial for heart attack

STENTYS S.A., a medical technology company commercializing the world's first and only Self-Apposing Stent to treat Acute Myocardial Infarction (AMI), announced today that it has enrolled the first patient in its 'APPOSITION IV' clinical study using its new Self-Apposing Sirolimus-eluting stent.

From Medtronic 15 Jun 2012

Tooth scaling reduces CV disease risk

Taiwanese study results show that undergoing tooth scaling significantly reduces the risk for future myocardial infarction, stroke, and total cardiovascular events.

14 Jun 2012

Alpha-myosin triggers development of autoimmunity after heart attack

After people with type 1 diabetes have a heart attack, their long-term chance of suffering even more heart damage skyrockets. But the reason has long puzzled scientists. Now researchers at Joslin Diabetes Center have identified the misstep that sparks this runaway chronic damage and a promising way to block it.

14 Jun 2012